ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2011
18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.NMR in biomedicine · 2013Trial
- Examining correlations of oxygen sensitive MRI (BOLD/TOLD) with [American journal of nuclear medicine and molecular imaging · 2019Article
- [EJNMMI research · 2017Article
- Changes in tumor oxygen state after sorafenib therapy evaluated byOncology letters · 2017Article
- Quantitative [Molecular imaging and biology · 2017Article
- Quantitative Analysis of [Molecular imaging and biology · 2017Article
- Molecular mechanisms of hypoxia in cancer.Clinical and translational imaging · 2017Review
- 2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth.Anti-cancer agents in medicinal chemistry · 2017Article
- Tumor hypoxia: a new PET imaging biomarker in clinical oncology.International journal of clinical oncology · 2016Review
- Dynamic oxygen challenge evaluated by NMR T1 and T2*--insights into tumor oxygenation.NMR in biomedicine · 2015Article
- 18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.PloS one · 2015Article
- Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI.American journal of nuclear medicine and molecular imaging · 2015Article
- Positron emission tomography to assess hypoxia and perfusion in lung cancer.World journal of clinical oncology · 2014Review
- Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.Molecular pharmaceutics · 2014Article
- Targeting breast tumors with pH (low) insertion peptides.Molecular pharmaceutics · 2014Article
- Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014Article
- A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2014Article
- Reproducibility of static and dynamic (18)F-FDG, (18)F-FLT, and (18)F-FMISO MicroPET studies in a murine model of HER2+ breast cancer.Molecular imaging and biology · 2013Article
- Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.Disease models & mechanisms · 2012Review
- Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.International journal of oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
Abstract
unlabelledThe aim of this study was to evaluate (18)F-fluromisonidazole ((18)F-FMISO) PET for monitoring the tumor response to the antivascular compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA; vadimezan).
methods(18)F-FMISO PET was performed 3 h before and 24 h after treatment with DMXAA (20 mg/kg) in mice bearing HT29 xenograft tumors. Pimonidazole was coadministered with the first (18)F-FMISO injection, and 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide (EF5) was coadministered with the second one. Hoechst 33342 was administered 5 min before sacrifice. Digital autoradiograms of tumor sections were acquired; this acquisition was followed by immunofluorescence microscopic visualization of pimonidazole, EF5, the Hoechst 33342, CD31, and α-smooth muscle actin.
resultsDMXAA treatment resulted in a marked reduction in the (18)F-FMISO mean standardized uptake value (SUV(mean)) in approximately half of the treated tumors. The reduction in SUV(mean) correlated with a decrease in the fraction of tumor area staining positive for both EF5 and pimonidazole. Compared with untreated controls, tumors with decreasing SUV(mean) had significantly fewer perfused microvessels.
conclusion(18)F-FMISO PET could distinguish between different tumor responses to DMXAA treatment. However, a reduction in (18)F-FMISO SUV(mean) after DMXAA treatment was indicative of reduced perfusion and therefore delivery of (18)F-FMISO, rather than a reduction in tumor hypoxia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.